- Disease: Post COVID-19 condition
- Study type: Randomised Clinical Trial, Treatment
- Study type descriptors: Interventional
- Objective: To investigate the efficacy, pharmacodynamics and safety of BC 007 in improving long COVID symptoms by neutralising functional autoantibodies targeting G-protein
- Number of participants enrolled: 119
- Study enrolling from to
- Study includes follow-up for 3 months
Sites (16)
- Hospital General Universitario de Alicante Doctor Balmis (Alicante, Spain)
- University Hospital Cologne (Cologne, Germany)
- Stadtspital Zürich (Zurich, Switzerland)
- University Hospital Münster (Münster, Germany)
- University Hospital Erlangen (Erlangen, Germany)
- Hospital Universitario Quirónsalud Madrid (Madrid, Spain)
- Klinik Floridsdorf – Wiener Gesundheitsverbund (Vienna, Austria)
- Terveystalo Helsinki Sleep Clinic (Helsinki, Finland)
- Jena University Hospital (Jena, Germany)
- University Medical Center Freiburg (Freiburg, Germany)
- University Hospital Heidelberg (Heidelberg, Germany)
- Charité – Universitätsmedizin Berlin (Berlin, Germany)
- Klinik Favoriten – Wiener Gesundheitsverbund (Vienna, Austria)
- Gemeinschaftskrankenhaus Havelhöhe (Berlin, Germany)
- Hospital Regional Universitario de Málaga (Málaga, Spain)
- Virgen del Rocío University Hospital (Seville, Spain)
Study Data
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- BC 007
External Links
Other information
Funders/Sponsors:
- Berlin Cures GmbH
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to